Ocugen Inc.’s request for emergency use authorization of the COVID-19 vaccine Covaxin in children and adolescents appears to lack alignment with US Food and Drug Administration recommendations on the amount and type of data it expects to see in a pediatric vaccine EUA request.
Based upon the FDA’s publicly disclosed evidentiary expectations, there are several aspects of Ocugen’s data package that put it at...







